A5090805323- Lung Cancer Research Studies
- Lung Cancer Treatments and Mutations
- Cancer Immunotherapy and Biomarkers
- Cancer therapeutics and mechanisms
- Estrogen and related hormone effects
- RNA modifications and cancer
- Metastasis and carcinoma case studies
- Immunotherapy and Immune Responses
- Radiopharmaceutical Chemistry and Applications
- Cancer, Hypoxia, and Metabolism
- Cytokine Signaling Pathways and Interactions
- Ion Channels and Receptors
- Immune cells in cancer
- Synthesis and biological activity
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Monoclonal and Polyclonal Antibodies Research
- Cancer-related molecular mechanisms research
- Drug Transport and Resistance Mechanisms
- Bioactive Compounds and Antitumor Agents
- Inflammatory mediators and NSAID effects
- Ferroptosis and cancer prognosis
- Cancer, Lipids, and Metabolism
- Cancer, Stress, Anesthesia, and Immune Response
- PI3K/AKT/mTOR signaling in cancer
- Neuroinflammation and Neurodegeneration Mechanisms
University of Turin
2020-2024
Akdeniz University Hospital
2024
Akdeniz University
2018-2022
Antalya IVF
2021
University of Alberta
1993
The ATP Binding Cassette transporter B1 (ABCB1) induces chemoresistance in osteosarcoma, because it effluxes doxorubicin, reducing the intracellular accumulation, toxicity, and immunogenic cell death induced by drug. A1 (ABCA1) isopentenyl pyrophosphate (IPP), a strong activator of anti-tumor Vγ9Vδ2 T-cells. Recruiting this population may represent an alternative strategy to rescue doxorubicin efficacy ABCB1-expressing osteosarcoma. In work, we analyzed how ABCA1 ABCB1 are regulated if...
Solid tumors subjected to intermittent hypoxia are characterized by resistance chemotherapy and immune-killing effector T-lymphocytes, particularly tumor-infiltrating Vγ9Vδ2 T-lymphocytes. The molecular circuitries determining this double not known.We analyzed a panel of 28 human non-small cell lung cancer (NSCLC) lines, using an in vitro system simulating continuous hypoxia. Chemosensitivity cisplatin docetaxel was evaluated chemiluminescence, ex vivo T-lymphocyte expansion flow cytometry....
The mechanism by which GH-releasing peptides elicit GH secretion has remained largely unknown. In this study, the effects of a second generation peptide, Ala-His-D-beta Nal-Ala-Trp-D-Phe-Lys-NH2(GHRP-1), on cAMP, intracellular Ca2+ ([Ca2+]i), and release were examined using rat pituitary gland static monolayer cell cultures. It was found that GHRP-1 increased in dose-dependent manner up to 3-fold, while having no effect cAMP levels. contrast, simultaneous elevations observed after treatment...
Doxorubicin is a strong inducer of immunogenic cell death (ICD), but it ineffective in P-glycoprotein (Pgp)-expressing cells. Indeed, Pgp effluxes doxorubicin and impairs the immunesensitizing functions calreticulin (CRT), an “eat-me” signal mediating ICD. It unknown if classical inhibitors, designed to reverse chemoresistance, may restore We addressed this question by using Pgp-expressing cancer cells, treated with Tariquidar, clinically approved inhibitor, R-3 compound,...
The response to immune checkpoint inhibitors (ICI) often differs between genders in non-small cell lung cancer (NSCLC), but metanalyses results are controversial, and no clear mechanisms defined. We aim at clarifying the molecular circuitries explaining differential gender-related anti-PD-1/anti-PD-L1 agents NSCLC.We prospectively analyzed a cohort of patients with NSCLC treated ICI as first-line approach, we identified determining efficacy 29 lines both genders, recapitulating patients'...
Abstract Melanomas are characterised by accelerated cell proliferation and metabolic reprogramming resulting from the contemporary dysregulation of MAPK pathway, glycolysis tricarboxylic acid (TCA) cycle. Here, we suggest that oncogenic transcription factor EB (TFEB), a key regulator lysosomal biogenesis function, controls melanoma tumour growth through transcriptional programme targeting ERK1/2 activity glucose, glutamine cholesterol metabolism. Mechanistically, TFEB binds negatively...
Glioblastoma multiforme (GBM) is an aggressive tumor, difficult to treat pharmacologically because of the blood-brain barrier (BBB), which rich in ATP-binding cassette (ABC) transporters and tight junction (TJ) proteins. The BBB disrupted within GBM bulk, but it competent brain-adjacent-to-tumor areas, where eventual foci can trigger tumor relapse. How cells influence permeability poorly investigated.
CD200 is a widely expressed cell surface glycoprotein that inhibits excessive inflammation in autoimmunity, transplantation, and viral infections. We previously observed visceral metastasis of highly aggressive inflammatory 4THM breast carcinoma cells was markedly decreased transgenic mice. The goal this study to determine whether exogenous exposure CD200fc mimics the effects endogenously over CD200. Female BALB/c mice were injected with two times week for five times. Injection started days...
In non-small cell lung cancer (NSCLC) the efficacy of chemo-immunotherapy is affected by high expression drug efflux transporters as ABCC1 and low ABCA1, mediating isopentenyl pyrophosphate (IPP)-dependent anti-tumor activation Vγ9Vδ2 T-lymphocytes. endothelial cells ABCA1 a predicted target transcription factor EB (TFEB), but no data exists on correlation between TFEB ABC involved in chemo-immuno-resistance NSCLC.
Background and Purpose: The transient receptor potential vanilloid 1 (TRPV1) ion channels enhance cytotoxic immune response may have therapeutic in cancer treatment. Hence, we here determined how activation of TRPV1 alters tumor-bearing mice. Experimental Approach: Three different metastatic subset 4T1 breast carcinoma cells were used to induce tumors Balb-c Mix leukocyte cultures (MLCs) using spleens draining lymph nodes prepared stimulated with various challenges. Effects four agonists,...
Download This Paper Open PDF in Browser Add to My Library Share: Permalink Using these links will ensure access this page indefinitely Copy URL DOI
<p>Dose-dependent effects of fulvestrant and letrozole. ERα highNCI-H1975 cells were grown 24 h in fresh medium (Ctrl) or containing 0.1, 1, 10 nM fluvestrant (Fulv, panel a), an inhibitor, letrozole (Letr, b), aromatase inhibitor. As read-out assays, the expression ERα-target gene CXCL12 was measured by RT-PCR triplicate (panel amount 17-β-estradiol ELISA (technical duplicate, b). The relative Ctrl considered 1. Data are means+SD (n=3, biological replicates). *p<0.05,...
<p>Outcome of non-small cell lung cancer patients in LUAD TCGA cohort. a. OS adenocarcinoma (LUAD) dataset The Cancer Genome Atlas (TCGA), stratified according to the gender. F: females; M: males. b-c. female and male patients, median expression value CD274/PD-L1 mRNA. d-e. ESR1/ERα f-g. co-expression phenotypes: CD274high/ESR1high, CD274high/ESR1low, CD274low/ESR1high, CD274low/ESR1low. P:0.005 for CD274high/ESR1high versus CD274low/ESR1low group. h. Expression ERα mRNA, plotted PD-L1...
<p>Immunohistochemical characterization of PD-L1 and ERα in non-small cell lung cancer samples. a. Representative immunohistochemical images one NSCLC patient classified as PD-L1low (tumor proportion score, TPS: 60%) PD-L1high (TPS: 90%), according to the internal scale used our prospective study (see Results section for details). Bar: 20 µm. b. phospho(Ser118)ERα from ERαlow (Histo-score, Hscore: 30 cytosolic ERα, 90 nuclear ERα) ERαhigh (Hscore: 270 240 study. One ER+ (score:3+) ER-...
<p>Disaggregated data of ERα, 17-β-estradiol and PD-L1 levels in non-small cell lung cancer cells. a-c. Expression ERα mRNA, measured by RT-PCR (technical triplicates) (panel a), 17-β-estradiol, ELISA b), expression surface c), flow cytometry 29 human NSCLC lines, divided female (F)- or male (M)-derived primary tumor (P) metastatic (MTS) localization-derived non-smoker (NSm) smoker (Sm) patients. *p<0.05, **p<0.01: F versus M, P MTS, NSm Sm (ANOVA).</p>
<p>Molecular circuitries linking ERα and PD-L1. ERα, activated by the binding of 17-β-estradiol phosphorylation on Ser118 via EGFR/Akt EGFR/ERK1/2 axes, upregulates PD-L1 predicts a better response to pembrolizumab. However, lowering synthesis with letrozole or activity fulvestrant sensitizes non-small cell lung cancer pembrolizumab, relieving PD-L1-dependent immune-suppression, allowing expansion anti-tumor infiltrating lymphocytes, such as CD8+T-cells, NK cells Vγ9Vδ2+T cells. We...